Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.9152W HIGH $28.82
Volume
586.88 K
Value Traded
29.38 M
Short % Float
4.13%
+2.34%Week
-2.14%1 Month
-25.21%3 Month
-5.81%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.60 B
EPS (TTM)
0.22
P/E Ratio
92.35
Ent. Value
2.18 B
Total Shares
127.69 M
Float Shares
118.65 M
Insiders
7.11%
Institutions
92.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PRVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Privia Health Group, Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How PRVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Privia Health Group, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PRVA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mountcastle DavidOfficer (EVP & Chief Financial Officer) | Sell | -21,275 164,853 held | $27.67 | 07/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.4 % (-33.3 %) | 8.50 M | 466.80 K | -38.92% ( -297.40 K) |
PRVA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRVA ranks across every disease it competes in
Competitive Position is a premium feature
See how PRVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRVA News
-PRVA
Oct 5, 2026▲ +0.4%today
Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement
Anthem Blue Cross and Blue Shield in Virginia has finalized a new agreement with Privia Health, ensuring that Anthem members can continue to access Privia Medical Group physicians in-network. This partnership emphasizes a commitment to high-quality healthcare and aims to promote value-based care while maintaining affordability for Virginians.
Read more →-PRVA
Aug 18, 2026Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
Privia Health Group, Inc. has appointed Dr. Opella Ernest to its Board of Directors, effective September 1, 2026. Dr. Ernest, who has over 20 years of healthcare executive experience, will also serve on the Compliance Committee. Her expertise in clinical operations and value-based care is anticipated to benefit Privia as it expands its provider networks.
Read more →-PRVA
Aug 6, 2026▼ -8.2%on this news
Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
Privia Health Group, Inc. reported strong financial results for the second quarter and first half of 2026, with a net income of $9.0 million, marking a 236.7% increase from the same period in 2025. The company also reported an adjusted EBITDA of $37.4 million, up 29.1% year-over-year. Additionally, Privia raised its full-year guidance for key financial metrics, indicating positive growth expectations.
Read more →-PRVA
Jul 7, 2026Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
Privia Health Group, Inc. will announce its second-quarter financial results on August 6, 2026, before market opening. The press release will be available at 7:00 am ET, followed by a conference call at 8:00 am ET to discuss the results and future outlook. The company emphasizes its commitment to enhancing healthcare delivery and patient outcomes.
Read more →-PRVA
May 27, 2026Privia Health Enters New Jersey
Privia Health Group, Inc. has announced a partnership with the Neurology Group of Bergen County to enter New Jersey. This collaboration aims to enhance care delivery through the Privia Platform by the end of 2026. The partnership is expected to improve access to high-quality neurological care while maintaining the independent culture of NGBC.
Read more →-PRVA
May 7, 2026Privia Health Reports First Quarter 2026 Financial Results - Strong First Quarter Performance and Operating Execution - Reiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the first quarter of 2026, showcasing strong performance with a 25.8% increase in total revenue, amounting to $603.8 million. The adjusted EBITDA rose by 36.3% compared to the same quarter last year. While the company reiterated its full-year guidance and raised the range for attributed lives, it experienced a decline in net income and net income per share versus the previous year.
Read more →-PRVA
Mar 24, 2026Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
Privia Health Group, Inc. has been awarded the 2026 MAP Award for High Performance in Revenue Cycle by HFMA. This recognition, given for excellence in revenue cycle metrics, marks the ninth time in ten years that Privia has received this honor. The award reflects the company's commitment to patient-centered practices and innovative strategies that enhance operational efficiency.
Read more →-PRVA
Mar 4, 2026Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
Privia Health's colorectal cancer screening program, supported by Amalgam Rx and Exact Sciences, achieved an 84% screening rate in 2024, surpassing national goals. The program utilized EHR-enabled workflows and proactive patient outreach to enhance screening accessibility. Launched in 2023, it aims to improve preventive care initiatives while reducing administrative burdens for healthcare providers.
Read more →-PRVA
Feb 26, 2026▲ +10%on this news
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
Privia Health Group, Inc. announced its financial results for Q4 and full year 2025, showcasing strong performance metrics that exceeded guidance. The company reported a 49.5% increase in net cash provided by operating activities compared to 2024, alongside a solid balance sheet with no debt. Looking ahead, Privia aims to maintain its growth trajectory in 2026.
Read more →-PRVA
Jan 22, 2026Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. will release its financial results for Q4 and the full year 2025 on February 26, 2026. The results will be available before market open, followed by a conference call to discuss the outcomes and future outlook. The company emphasizes its commitment to enhancing healthcare delivery.
Read more →-PRVA
Nov 6, 2025Privia Health Reports Third Quarter 2025 Financial Results - Very Strong Third Quarter and Year-to-Date Performance Across the Business - Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24 - Implemented Provi
Privia Health Group, Inc. has reported strong financial results for the third quarter of 2025, revealing a 94.1% increase in net income and a 61.6% rise in adjusted EBITDA compared to the same period last year. The company has also raised its full-year 2025 guidance, reflecting expectations for continued growth across key metrics. Furthermore, Privia showcased a robust performance in its Medicare Shared Savings Program, achieving significant shared savings. The company is poised for further growth as it proceeds with the acquisition of an ACO business that will enhance its value-based care footprint.
Read more →-PRVA
Sep 23, 2025would," "could," "should," and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements r
Privia Health Group, Inc. announced its acquisition of an Accountable Care Organization (ACO) business from Evolent Health, which cares for over 120,000 attributed lives. This move will expand Privia's reach in value-based care arrangements, serving approximately 1.5 million attributed lives across various programs. The acquisition, costing $100 million with an additional $13 million based on performance, is expected to enhance Privia's Adjusted EBITDA in 2026. The transaction underscores Privia's strategy to integrate new providers into its extensive network and technology platform, aiming for improved patient outcomes and cost-effectiveness.
Read more →-PRVA
Aug 29, 2025▲ +5.6%on this news
financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal informatio
Privia Health Group, Inc. reported impressive results from its Accountable Care Organizations (ACOs) in the 2024 Medicare Shared Savings Program, achieving over $233 million in shared savings, marking a 32% increase from the previous year. The firm's Mid-Atlantic ACO delivered the highest savings rate of 10.6%, showcasing the effectiveness of its physician-led model. Additionally, the company has raised its Adjusted EBITDA guidance for full-year 2025 to between $113 to $116 million, reflecting its strong operational performance and growth strategy.
Read more →-PRVA
Aug 7, 2025Privia Health Reports Second Quarter 2025 Financial Results - Very Strong First Half Performance Across All Key Operating and Financial Metrics - Implemented Providers +13.8% and Practice Collections +18.5% compared to 2
Privia Health Group, Inc. has reported strong financial results for the second quarter of 2025, showcasing a total revenue increase of 23.4% compared to the same quarter in 2024. Key metrics such as practice collections and adjusted EBITDA saw significant growth, leading the company to raise its financial guidance for the full year 2025. Despite the positive performance, there was a noted decline in operating income and net income compared to last year. Overall, the results reflect continued strength in the company's services and expansion strategy.
Read more →-PRVA
Jul 8, 2025does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Contac
Privia Health Group, Inc. has appointed Lance V. Berberian to its Board of Directors, effective July 15, 2025. Berberian, who has over 30 years of experience in technology strategy and cybersecurity, will also serve on the Audit Committee. His appointment increases the board's composition to 10 members, and the company hopes to leverage his expertise for continued growth in building provider networks across the U.S. Privia Health focuses on transforming healthcare delivery to improve outcomes and lower costs.
Read more →-PRVA
May 8, 2025▲ +7.5%on this news
Privia Health Reports First Quarter 2025 Financial Results - Strong First Quarter Performance and Operating Execution - Enters the State of Arizona - Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges f
Privia Health Group, Inc. reported positive financial results for Q1 2025, with significant increases in revenue, gross profit, and operating income compared to the previous year. The company has entered the state of Arizona through a partnership with Integrated Medical Services, aiming to expand its provider network and manage more patient lives in value-based care arrangements. Additionally, Privia has raised its full-year guidance for 2025 to the mid- to high end of its previous projections, reflecting confidence in its operational performance and growth potential.
Read more →-PRVA
Feb 27, 2025▲ +5.8%on this news
Privia Health Reports Fourth Quarter and Full-Year 2024 Financial Results - All 2024 Operating and Financial Metrics Above High End of Guidance Ranges - Very strong New Provider Signings Implemented Providers +11.2% from
Privia Health Group, Inc. announced its financial results for the fourth quarter and full year of 2024, reporting that all operating and financial metrics surpassed the high end of their guidance ranges. Key highlights include a strong increase in new provider signings, which rose by 11.2% year-over-year, and a notable 35.3% increase in net cash provided by operating activities, totaling $109.3 million. However, the company experienced a decline in net income and operating income compared to the previous year. For 2025, Privia is focusing on provider growth and navigating a challenging Medicare Advantage environment while aiming for profitable growth.
Read more →-PRVA
Nov 7, 2024▲ +6.5%on this news
Privia Health Reports Third Quarter 2024 Financial Results - Strong Execution Across All Business and Financial Metrics - Raised Full-Year 2024 Guidance to At or Above the High End for All Metrics - Announced New Market
Privia Health Group, Inc. (Nasdaq: PRVA) announced its financial results for the third quarter and nine months ending September 30, 2024, showcasing strong performance across various business metrics. The company reported total revenue of $437.9 million, an increase of 4.9%, and adjusted EBITDA growth of 25.8%. Privia Health has raised its full-year 2024 guidance for key financial metrics, supported by the successful entry into the Indiana market. However, despite these successes, net income showed a significant decline of 37.4% year-over-year.
Read more →-PRVA
Aug 8, 2024▲ +5.9%on this news
Privia Health Reports Second Quarter 2024 Financial Results - Strong Execution Across All Business and Financial Metrics - Raised Full-Year 2024 Guidance to Mid to High End for All Metrics ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the second quarter and first six months of 2024, showcasing a revenue increase of 4.7% year-over-year and solid growth in adjusted EBITDA. Despite a declining net income and operating income, the company raised its full-year guidance across key financial metrics, reflecting confidence in its operational strategies. The financial health remains robust with significant cash reserves and a strong provider network.
Read more →-PRVA
May 9, 2024Privia Health Reports First Quarter 2024 Financial Results - Practice Collections +7.4% compared to 1Q'23 - Implemented Providers +17.3% compared to 1Q'23 - Company Reiterated Full Year 2024 Guidance ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the first quarter of 2024, showing a 7.5% increase in total revenue to $415.2 million, alongside strong growth in practice collections and implemented providers. The company successfully grew implemented providers by 17.3% year-over-year, while adjusted EBITDA increased by 18.1%. Despite these strong performance indicators, the company noted a significant decline in operating income and net income compared to the previous year. Privia reiterated its full-year guidance amid concerns regarding future practice collections due to renegotiated Medicare Advantage agreements.
Read more →About Privia Health Group, Inc. Common Stock
Headquarters950 N. GLEBE RD., SUITE 700, ARLINGTON, VA, 22203
BIOPHARMAWATCH ELITE PLUS
Trade the next PRVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime